CD274 and neoplasm: Studies have shown that the level of tumor mutational burden (TMB) status, programmed death-ligand 1 (PD-L1) expression, and tumor-infiltrating lymphocytes (TILs) are strongly correlated with the effectiveness of checkpoint inhibitors in certain types of cancer.